# EDGAR Filing Document

**Accession Number:** 0001697862
**File Stem:** 0001104659-26-076606
**Filing Date:** 2026-6
**Character Count:** 6064
**Document Hash:** 4d26492aca5288ba24d08e569c7bd836
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-076606.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0001104659-26-076606

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260623

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARGENX SE
- **CENTRAL INDEX KEY:** 0001697862
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38097
- **FILM NUMBER:** 261108873

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** INDUSTRIEPARK ZWIJNAARDE 7
- **STREET 2:** BUILDING C B-9052
- **CITY:** ZWIJNAARDE
- **NON US STATE TERRITORY:** GHENT
- **PROVINCE COUNTRY:** C9
- **BUSINESS PHONE:** 32 (9) 310 34 00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** INDUSTRIEPARK ZWIJNAARDE 7
- **STREET 2:** BUILDING C B-9052
- **CITY:** ZWIJNAARDE
- **NON US STATE TERRITORY:** GHENT
- **PROVINCE COUNTRY:** C9

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** argenx N.V
- **DATE OF NAME CHANGE:** 20170210

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2026**

**Commission File Number: 001-38097**

**ARGENX SE**

(Translation of registrant's name into English)

**Laarderhoogtweg 25<br> 1101 EB Amsterdam, the Netherlands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**<u>EXPLANATORY NOTE</u>**

On June 23, 2026, argenx SE (the "<u>Company</u>") issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

*The information contained in this Current Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the Company's Registration Statements on Forms S-8 (File Nos. [333-225375](https://www.sec.gov/Archives/edgar/data/1697862/000110465918037616/a18-14643_3s8.htm), [333-258253](https://www.sec.gov/Archives/edgar/data/1697862/000110465921097298/tm2123453d1_s8.htm), [333-274721](https://www.sec.gov/Archives/edgar/data/1697862/000110465923104307/tm2326371d1_s8.htm), and [333-292200](https://www.sec.gov/Archives/edgar/data/1697862/000110465925122044/tm2533221d1_s8.htm)), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.*

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](tm2618529d1_ex99-1.htm) | [Press Release June 23, 2026](tm2618529d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ARGENX SE** | **ARGENX SE** |
| Date: June 23, 2026 | By: | /s/ Hemamalini (Malini) Moorthy |
|  |  | Name: Hemamalini (Malini) Moorthy<br> Title: General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2618529d1_ex99-1img001.jpg)

**argenx to Host Autoimmune Myositis R&D Webinar**

**June 23, 2026, 7:00 AM CET**

**Amsterdam, the Netherlands** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled "R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis" today, June 23, 2026, at 2:00pm ET.

argenx management and scientific leadership will be joined by external key opinion leaders:

&nbsp;&nbsp;&nbsp;&nbsp;· **Avery LaChance, MD, MPH, FAAD**, Associate Professor of Dermatology, Harvard Medical School;
 Director of Connective Tissue Disease Clinic

&nbsp;&nbsp;&nbsp;&nbsp;· **Arjun Seth, MD**, Assistant Professor, Neurology (Neuromuscular Disease), Northwestern University
 Feinberg School of Medicine

&nbsp;&nbsp;&nbsp;&nbsp;· **Rohit Aggarwal, MD, MS**, Professor of Medicine, University of Pittsburgh, and Co-Director of
 UPMC Myositis Center

**Webcast Information**

A live webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Additional materials, including supporting presentation slides, will be available on argenx's <u>Events & Presentations</u> website today at 2:00pm ET.

**About argenx**

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit <u>www.argenx.com</u> and follow us on <u>LinkedIn</u>, <u>Instagram</u>, <u>Facebook</u>, and <u>YouTube</u>.

**Contacts**

**Media:**

Colin McBean

<u>cmcbean@argenx.com</u>

**Investors:**

Alexandra Roy

<u>aroy@argenx.com</u>